The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Maplebear Inc
NASDAQ:CART
|
US |
|
Sagimet Biosciences Inc
NASDAQ:SGMT
|
US |
|
Almonty Industries Inc
NASDAQ:ALM
|
CA |
|
Lemonade Inc
LSE:0A91
|
US |
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
AU |
|
Nauka-Svyaz' PAO
MOEX:NSVZ
|
RU |
|
I
|
Imagion Biosystems Ltd
OTC:IBXXF
|
AU |
|
A
|
Aristocrat Leisure Ltd
SWB:AC8
|
AU |
|
Advanced Media Inc
TSE:3773
|
JP |
|
B
|
Bridgestone Corp
XMUN:BGT
|
JP |
|
Wickes Group PLC
F:0FD
|
UK |
|
H
|
Hang Lung Properties Ltd
XMUN:AOP
|
HK |
|
Compagnie Financiere Richemont SA
SIX:CFR
|
CH |
|
Vidrala SA
MAD:VID
|
ES |
|
T
|
Toray Industries Inc
F:6HK
|
JP |
|
E
|
Edenred SE
F:QSV
|
FR |
|
C
|
China Aerospace International Holdings Ltd
OTC:CHAEF
|
HK |
|
N
|
NVIDIA Corp
XMUN:NVD
|
US |
|
M
|
McCoy Global Inc
OTC:MCCRF
|
CA |
|
O
|
Ocean Bio-Chem Inc
F:OBC
|
US |
|
C
|
CECONOMY AG
OTC:MTTRY
|
DE |
|
A
|
Abercrombie & Fitch Co
DUS:AFT
|
US |
|
N
|
Neptune Digital Assets Corp
F:1NW
|
CA |
|
Sagimet Biosciences Inc
F:0O2
|
US |
Maplebear Inc (CART)’s 12-month stock price forecast through October 2027 has a consensus target of $57.12, implying 2% downside. The forecast is based on price targets from 31 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for CART is 57.12 USD with a low forecast of 45.26 USD and a high forecast of 80.85 USD.
Over the last 5 years, the compound annual growth rate for Revenue has been 20%. The projected CAGR for the next 8 years is 6%.
Over the last 5 years, the compound annual growth rate for Gross Profit has been 35%. The projected CAGR for the next 8 years is 7%.
The compound annual growth rate for Operating Income over the next 8 years is 7%.
The compound annual growth rate for Pre-Tax Income over the next 3 years is 27%.
The compound annual growth rate for Net Income over the next 8 years is 5%.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more